[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"raynaud-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:raynaud-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100492963","phase-3-evaluation-of-botulinum-toxin-type-a-in-the-treatment-of-buergers-disease-100492963",false,"NCT05698979","Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease","BETOX","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. patient with Buerger's disease according to Olin criteria (ref)\n3. with digital ischemia with critical upper or lower limb ischemia criteria defined as Upper limb: pain and\u002For trophic disorders for at least 15 days AND digital pressure less than 50 mmHg Or TCPO2 30 mmHg) Or\u002Fand Lower limb: pain and\u002For trophic disorders for at least 15 days AND ankle pressure less than 50 mmHg (70 mmHg if diabetes), or 30 mmHg at the toe (50 mmHg if diabetes) or TCPO2 30 mmHg).\n4. Ability to attend study visits\n5. Ability to complete daily study agenda\n6. Ability to give free and informed consent\n7. Membership of a Social Security scheme\n\nExclusion Criteria:\n\n1. History of myasthenia gravis or Eaton-Lambert syndrome\n2. History of inflammatory myositis for less than 2 years or pre-existing motor neuron disease or superior limb neuropathy.\n3. Known allergy to botulinum toxin or cream lidocaine, albumin or inhaled nitrous oxide\u002Foxygen.\n4. Progressive infection of one hand or foot\n5. Aminoglycoside treatment\n6. Pregnant or nursing women\n7. History of vascular surgery of surgical sympathectomy of upper or lower limb\n8. Revascularization procedure considered within 3 months of inclusion\n9. Risk of major amputation within 3 months of inclusion\n10. Iloprost expected within one month of study treatment\n11. Hyperbaric chamber sessions scheduled within one month of study treatment\n12. Life expectancy less than 6 months\n13. Contraindication to one or more of the following products: BOTOX 100 UNITS ALLERGAN, LIDOCAINE\u002FPRILOCAINE 5%, cream or NITROUS OXIDE MEDICINAL\n14. Patients treated by class III anti arhythmic drugs for example amiodarone 15 ) Patient with guardians, curators, or protection of justice","ALL","18 Years",{"count":19,"type":20},8,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.",[26,27],"Buerger Disease","Raynaud Syndrome",[29,30,31,32,33,34],"botulinum toxin A","botox","feasibility","raynaud","buerger","tolerance","NOT_YET_RECRUITING","2026-05-28",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":20},"2027-01-01",{"date":43,"type":20},"2028-02",{"name":45,"class":46},"University Hospital, Toulouse","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443","NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":55,"type":20},100,[57],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[60,61,62,63,64,65,66,67,68,69,70,71,27,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","2026-05-01",{"date":102,"type":39},"2026-05-05",{"date":104,"type":20},"2026-08",{"date":106,"type":20},"2035-12",{"name":108,"class":46},"Jay C. Buckey Jr."]